$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

$vrtx Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000087532017000030 Filed on April 28, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$714.7M	$398.1M
YoY Change	79.54%	187.4%
Cost Of Revenue	$46.99M	$49.79M
YoY Change	-5.63%	430.74%
Gross Profit	$667.7M	$348.3M
YoY Change	91.72%	169.73%
Gross Profit Margin	93.43%	87.49%
Selling, General & Admin	$113.3M	$105.2M
YoY Change	7.71%	22.54%
% of Gross Profit	16.97%	30.21%
Research & Development	$273.6M	$255.9M
YoY Change	6.92%	18.67%
% of Gross Profit	40.97%	73.46%
Depreciation & Amortization	$14.85M	$16.42M
YoY Change	-9.53%	0.32%
% of Gross Profit	2.22%	4.71%
Operating Expenses	$386.9M	$361.1M
YoY Change	7.15%	19.78%
Operating Profit	$270.8M	-$14.33M
YoY Change	-1990.03%	-91.67%
Interest Expense	-$16.77M	-$20.70M
YoY Change	-19.0%	-2.86%
% of Operating Profit	-6.19%
Other Income/Expense, Net	-$544.0K	$4.411M
YoY Change	-112.33%	-186.27%
Pretax Income	$253.5M	-$30.62M
YoY Change	-928.08%	-84.57%
Income Tax	$3.985M	$5.485M
% Of Pretax Income	1.57%
Net Earnings	$247.8M	-$41.63M
YoY Change	-695.12%	-79.04%
Net Earnings / Revenue	34.66%	-10.46%
Basic Earnings Per Share	$1.01	-$0.17
Diluted Earnings Per Share	$0.99	-$0.17
COMMON SHARES
Basic Shares Outstanding	246.0M shares	243.8M shares
Diluted Shares Outstanding	248.7M shares	243.8M shares

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.409B	$1.026B
YoY Change	37.33%	-13.12%
Cash & Equivalents	$1.004B	$604.2M
Short-Term Investments	$405.0M	$421.0M
Other Short-Term Assets	$173.0M	$132.0M
YoY Change	31.06%	109.52%
Inventory	$82.02M	$63.20M
Prepaid Expenses
Receivables	$208.0M	$181.9M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.872B	$1.403B
YoY Change	33.43%	3.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$708.4M	$690.5M
YoY Change	2.59%	-2.55%
Goodwill	$50.38M	$50.38M
YoY Change	0.0%	26.23%
Intangibles
YoY Change
Long-Term Investments	$20.00M	$30.00M
YoY Change	-33.33%
Other Assets	$11.49M	$7.600M
YoY Change	51.24%	-4.43%
Total Long-Term Assets	$1.075B	$1.085B
YoY Change	-0.94%	34.35%
TOTAL ASSETS
Total Short-Term Assets	$1.872B	$1.403B
Total Long-Term Assets	$1.075B	$1.085B
Total Assets	$2.947B	$2.488B
YoY Change	18.44%	14.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$63.15M	$75.22M
YoY Change	-16.05%	72.83%
Accrued Expenses	$278.0M	$272.7M
YoY Change	1.94%	54.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.00M	$164.0M
YoY Change	-88.41%	241.67%
Total Short-Term Liabilities	$489.8M	$552.0M
YoY Change	-11.28%	82.53%
LONG-TERM LIABILITIES
Long-Term Debt	$529.0M	$661.0M
YoY Change	-19.97%	-15.9%
Other Long-Term Liabilities	$28.47M	$31.82M
YoY Change	-10.54%	-2.67%
Total Long-Term Liabilities	$28.47M	$31.82M
YoY Change	-10.54%	-2.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$489.8M	$552.0M
Total Long-Term Liabilities	$28.47M	$31.82M
Total Liabilities	$1.264B	$1.372B
YoY Change	-7.86%	17.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.135B	-$5.303B
YoY Change	-3.17%	8.14%
Common Stock	$6.619B	$6.265B
YoY Change	5.65%	6.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.500B	$957.1M
YoY Change
Total Liabilities & Shareholders Equity	$2.947B	$2.488B
YoY Change	18.44%	14.87%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	$247.8M	-$41.63M
YoY Change	-695.12%	-79.04%
Depreciation, Depletion And Amortization	$14.85M	$16.42M
YoY Change	-9.53%	0.32%
Cash From Operating Activities	$265.7M	-$15.14M
YoY Change	-1855.25%	-93.19%
INVESTING ACTIVITIES
Capital Expenditures	$11.10M	$11.97M
YoY Change	-7.31%	13.41%
Acquisitions
YoY Change
Other Investing Activities	-$60.00K	-$80.00K
YoY Change	-25.0%	-89.99%
Cash From Investing Activities	-$161.0M	-$102.7M
YoY Change	56.73%	-147.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$289.6M	$4.702M
YoY Change	-6258.34%	-90.67%
NET CHANGE
Cash From Operating Activities	$265.7M	-$15.14M
Cash From Investing Activities	-$161.0M	-$102.7M
Cash From Financing Activities	-$289.6M	$4.702M
Net Change In Cash	-$183.5M	-$113.1M
YoY Change	62.15%	-368.01%
FREE CASH FLOW
Cash From Operating Activities	$265.7M	-$15.14M
Capital Expenditures	$11.10M	$11.97M
Free Cash Flow	$254.6M	-$27.11M
YoY Change	-1039.08%	-88.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000875320
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	249068782	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	VERTEX PHARMACEUTICALS INC / MA
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	61451000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	63145000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	201083000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	207955000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	315249000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	277962000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21173000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16025000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6506795000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	6616975000	USD
CY2016Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56246000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	69790000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55472000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	68982000	USD
CY2017Q1	us-gaap	Amount Of Ineffectiveness On Net Investment Hedges AmountOfIneffectivenessOnNetInvestmentHedges	0	USD
CY2016Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1946000	USD
CY2016Q4	us-gaap	Assets Assets	2896787000	USD
CY2017Q1	us-gaap	Assets Assets	2946703000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	1831540000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	1871814000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	250612000	USD
CY2017Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	405103000	USD
CY2016Q1	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gains Losses Sale Proceeds AvailableForSaleSecuritiesGrossRealizedGainsLossesSaleProceeds	0	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	19426000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	19270000	USD
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	248890834	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	248300517	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	248890834	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2450000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	2459000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48354000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	242608000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	5529000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1792000	USD
CY2016Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	34976000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	30355000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	714768000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	604245000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1183945000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1003679000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-110523000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-180266000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	248300517	shares
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-42825000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	244400000	USD
CY2016Q4	us-gaap	Cost Method Investments CostMethodInvestments	20276000	USD
CY2017Q1	us-gaap	Cost Method Investments CostMethodInvestments	20276000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	49789000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	46242000	USD
CY2016Q1	us-gaap	Costs And Expenses CostsAndExpenses	412410000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	443876000	USD
CY2016Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	73416000	USD
CY2017Q1	us-gaap	Customer Deposits Current CustomerDepositsCurrent	104774000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6005000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6057000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	6632000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	5742000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	134063000	USD
CY2017Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	135402000	USD
CY2017Q1	us-gaap	Deferred Tax Liability Not Recognized Amount Of Unrecognized Deferred Tax Liability Undistributed Earnings Of Foreign Subsidiaries DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries	0	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16415000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14850000	USD
CY2016Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	860000	USD
CY2017Q1	us-gaap	Direct Operating Cost Royalty Expense DirectOperatingCostRoyaltyExpense	746000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-30617000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	253533000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5485000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3985000	USD
CY2016Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	581000	USD
CY2017Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1164000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-343000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	717000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2512000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5118000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-29922000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-9931000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2620000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	1388000	USD
CY2016Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	845000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	808000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	50384000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	50384000	USD
CY2016Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2017Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2815000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-839000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4771000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3650000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	2060000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1212000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7325000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	47178000	USD
CY2016Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-2637000	USD
CY2017Q1	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-3198000	USD
CY2017Q1	us-gaap	Increase In Unrecognized Tax Benefits Is Reasonably Possible IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	0	USD
CY2016Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-20698000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-16765000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	20603000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	17527000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14584000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11927000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	77604000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	82020000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6348000	USD
CY2017Q1	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	284340000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10943000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10954000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41631000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	247350000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9172000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	56672000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	60921000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	1558596000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	1263910000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2896787000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2946703000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	792537000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	489796000	USD
CY2016Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	300000000	USD
CY2017Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	181609000	USD
CY2017Q1	us-gaap	Minority Interest MinorityInterest	182785000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4702000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-289565000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-102708000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-157781000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15137000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	265692000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-41631000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	247756000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	5529000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1792000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-41631000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	247355000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	12549000	USD
CY2017Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14330000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	270842000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11885000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11494000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1740000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2001000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6723000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5148000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-5212000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-6681000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	229000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3534000	USD
CY2016Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	284340000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-544000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28699000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28467000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3835000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	5152000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4411000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-80000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-60000	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4041000	USD
CY2017Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	4703000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	224624000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	248273000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11974000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11159000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	44564000	USD
CY2016Q1	us-gaap	Restructuring Charges RestructuringCharges	687000	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	9999000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	70534000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	128493000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	8846000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	11249000	USD
CY2016Q4	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	300000000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	131173000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	98393000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-36102000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	249548000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	698362000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	708395000	USD
CY2017Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	300000000	USD
CY2016Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2017Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	300000000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	103000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	117000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	255860000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	273563000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	47762000	USD
CY2016Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6047000	USD
CY2017Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	7634000	USD
CY2016Q4	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	1907000	USD
CY2017Q1	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	613000	USD
CY2016Q1	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	-1459000	USD
CY2017Q1	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	305000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5373836000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5135451000	USD
CY2016Q1	us-gaap	Revenues Revenues	398080000	USD
CY2017Q1	us-gaap	Revenues Revenues	714718000	USD
CY2016Q1	us-gaap	Royalty Revenue RoyaltyRevenue	3596000	USD
CY2017Q1	us-gaap	Royalty Revenue RoyaltyRevenue	1551000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	394410000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	480622000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	105214000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113326000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	55472000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	68982000	USD
CY2017Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	7536000	shares
CY2017Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	13598000	shares
CY2017Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	71.52
CY2017Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	82.60
CY2017Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y2M9D
CY2016Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	9149000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	31028000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	1156582000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	1500008000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1093628000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1116198000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1338191000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1682793000	USD
CY2017Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	616000	USD
CY2016Q1	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	0	USD
CY2017Q1	us-gaap	Undistributed Earnings Diluted UndistributedEarningsDiluted	-401000	USD
CY2016Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	0	USD
CY2017Q1	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	406000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2017Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	-2617000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	89201000	USD
CY2017Q1	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	89084000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	243831000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	248700000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	243831000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	246024000	shares
CY2016Q4	vrtx	Cash Cash Equivalents And Available For Sale Securities Fair Value CashCashEquivalentsAndAvailableForSaleSecuritiesFairValue	1434557000	USD
CY2017Q1	vrtx	Cash Cash Equivalents And Available For Sale Securities Fair Value CashCashEquivalentsAndAvailableForSaleSecuritiesFairValue	1408782000	USD
CY2016Q4	vrtx	Cash Cash Equivalents Available For Sale Securities Amortized Cost CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost	1413220000	USD
CY2017Q1	vrtx	Cash Cash Equivalents Available For Sale Securities Amortized Cost CashCashEquivalentsAvailableForSaleSecuritiesAmortizedCost	1382879000	USD
CY2016Q4	vrtx	Cash Cash Equivalents Availableforsale Securities Gross Unrealized Gain CashCashEquivalentsAvailableforsaleSecuritiesGrossUnrealizedGain	21422000	USD
CY2017Q1	vrtx	Cash Cash Equivalents Availableforsale Securities Gross Unrealized Gain CashCashEquivalentsAvailableforsaleSecuritiesGrossUnrealizedGain	26163000	USD
CY2016Q4	vrtx	Cash Cash Equivalents Availableforsale Securities Unrealized Loss Gross CashCashEquivalentsAvailableforsaleSecuritiesUnrealizedLossGross	85000	USD
CY2017Q1	vrtx	Cash Cash Equivalents Availableforsale Securities Unrealized Loss Gross CashCashEquivalentsAvailableforsaleSecuritiesUnrealizedLossGross	260000	USD
CY2016Q1	vrtx	Collaborative Revenues CollaborativeRevenues	74000	USD
CY2017Q1	vrtx	Collaborative Revenues CollaborativeRevenues	232545000	USD
CY2017Q1	vrtx	Collaborative Revenues Relatedto Upfront Payment Upon Deliveryof Licenseandto Researchand Development Transition Activities CollaborativeRevenuesRelatedtoUpfrontPaymentUponDeliveryofLicenseandtoResearchandDevelopmentTransitionActivities	231700000	USD
CY2016Q4	vrtx	Construction Financing Obligation Noncurrent ConstructionFinancingObligationNoncurrent	486359000	USD
CY2017Q1	vrtx	Construction Financing Obligation Noncurrent ConstructionFinancingObligationNoncurrent	498775000	USD
CY2016Q4	vrtx	Contingent Liabilities ContingentLiabilities	0	USD
CY2017Q1	vrtx	Contingent Liabilities ContingentLiabilities	0	USD
CY2017Q1	vrtx	Deferred Revenue Royalty Purchase Agreement DeferredRevenueRoyaltyPurchaseAgreement	11800000	USD
CY2016Q4	vrtx	Due To Collaborative Arrangement Counterparty DueToCollaborativeArrangementCounterparty	73423000	USD
CY2017Q1	vrtx	Due To Collaborative Arrangement Counterparty DueToCollaborativeArrangementCounterparty	74760000	USD
CY2017Q1	vrtx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	400000	USD
CY2016Q1	vrtx	Employee Benefit Plan Payable Receivable EmployeeBenefitPlanPayableReceivable	593000	USD
CY2017Q1	vrtx	Employee Benefit Plan Payable Receivable EmployeeBenefitPlanPayableReceivable	19847000	USD
CY2017Q1	vrtx	Income Tax Liability Associated With Variable Interest Entity IncomeTaxLiabilityAssociatedWithVariableInterestEntity	0	USD
CY2016Q1	vrtx	Incremental Common Shares Attributableto Dilutive Effect Other IncrementalCommonSharesAttributabletoDilutiveEffectOther	0	shares
CY2017Q1	vrtx	Incremental Common Shares Attributableto Dilutive Effect Other IncrementalCommonSharesAttributabletoDilutiveEffectOther	12000	shares
CY2017Q1	vrtx	Indemnification Claims IndemnificationClaims	0	USD
CY2016Q4	vrtx	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	300000000.0	USD
CY2016Q1	vrtx	Proceeds From Collaborative Funding ProceedsFromCollaborativeFunding	0	USD
CY2017Q1	vrtx	Proceeds From Collaborative Funding ProceedsFromCollaborativeFunding	5000000	USD
CY2008	vrtx	Proceeds From Sale Of Royalty Rights ProceedsFromSaleOfRoyaltyRights	160000000.0	USD
CY2016Q1	vrtx	Repaymentsof Collaborative Funding RepaymentsofCollaborativeFunding	0	USD
CY2017Q1	vrtx	Repaymentsof Collaborative Funding RepaymentsofCollaborativeFunding	994000	USD
CY2017Q1	vrtx	Valuation Allowances And Reserves Provision ValuationAllowancesAndReservesProvision	40668000	USD
CY2017Q1	vrtx	Valuation Allowances And Reserves Sales Credits Or Payments Current ValuationAllowancesAndReservesSalesCreditsOrPaymentsCurrent	38168000	USD
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with the calculation of revenues, inventories, research and development expenses, stock-based compensation expense, restructuring expense, the fair value of intangible assets, goodwill, contingent consideration, noncontrolling interest, the consolidation of VIEs, leases, the fair value of cash flow hedges and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div>

Files In Submission

Name	View Source	Status
0000875320-17-000030-index-headers.html	Edgar Link	pending
0000875320-17-000030-index.html	Edgar Link	pending
0000875320-17-000030.txt	Edgar Link	pending
0000875320-17-000030-xbrl.zip	Edgar Link	pending
a2017q110-q.htm	Edgar Link	pending
a2017q110-q_exhibit101.htm	Edgar Link	pending
a2017q110-q_exhibit102.htm	Edgar Link	pending
a2017q110-q_exhibit103.htm	Edgar Link	pending
a2017q110-q_exhibit311.htm	Edgar Link	pending
a2017q110-q_exhibit312.htm	Edgar Link	pending
a2017q110-q_exhibit321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrtx-20170331.xml	Edgar Link	completed
vrtx-20170331.xsd	Edgar Link	pending
vrtx-20170331_cal.xml	Edgar Link	unprocessable
vrtx-20170331_def.xml	Edgar Link	unprocessable
vrtx-20170331_lab.xml	Edgar Link	unprocessable
vrtx-20170331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

2017 Q1 Form 10-Q Financial Statement

#000087532017000030 Filed on April 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTX VERTEX PHARMACEUTICALS INC / MA Stock $vrtx

2017 Q1 Form 10-Q Financial Statement

#000087532017000030 Filed on April 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRTX
VERTEX PHARMACEUTICALS INC / MA Stock $vrtx